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Abstract: Breast cancer is an important cause of morbidity and mortality for women, yet a significant
proportion of variation in individual risk is unexplained. It is reasonable to infer that unexplained
breast cancer risks are caused by a myriad of exposures and their interactions with genetic factors.
Most epidemiological studies investigating environmental contribution to breast cancer risk have
focused on a limited set of exposures and outcomes based on a priori knowledge. We hypothesize that
by measuring a rich set of molecular information with omics (e.g., metabolomics and adductomics)
and comparing these profiles using a case-control design we can pinpoint novel environmental risk
factors. Specifically, exposome-wide association study approaches can be used to compare molecular
profiles between controls and either breast cancer cases or participants with phenotypic measures
associated with breast cancer (e.g., high breast density, chronic inflammation). Current challenges
in annotating compound peaks from biological samples can be addressed by creating libraries of
environmental chemicals that are breast cancer relevant using publicly available high throughput
exposure and toxicity data, and by mass spectra fragmentation. This line of discovery and innovation
will extend understanding of how environmental exposures interact with genetics to affect health,
and provide evidence to support new breast cancer prevention strategies.
Keywords: breast cancer; exposome; metabolomics; adductomics
1. Introduction
Breast cancer is the most common cancer in women worldwide, and is a major cause of death for
women in mid-life [1]. In fact, breast cancer in women ages 20–49 is six times more prevalent than
any cancer in men [2]. Despite interest in identifying preventable causes of breast cancer, a significant
proportion of variation in individual breast cancer risk is unexplained [3,4], and so new approaches to
prevention are needed.
Increasing evidence suggests that environmental factors, rather that inherited genetic factors,
are the major causes of chronic diseases, including breast cancer. Studies of cohorts of 44,788 pairs
of Western European monozygotic twins estimated that the genetic population attributable fraction
for breast cancer was 31% (95% CI: 11–51%) [5,6]. In other words, 31% of breast cancer cases were
attributed to inherited genetic factors in this population.
While several environmental factors, including history of hormone replacement therapy,
reproductive history, alcohol consumption, and physical activity are associated with breast cancer
risk [7,8], risk ratios (RRs) or odds ratios (ORs) are modest (e.g., ORs range from 1 to 2). It is reasonable
to infer that unexplained breast cancer risks are caused by a myriad of environmental exposures—the
exposome—and their interactions with genetic factors. Here, the exposome is defined as the cumulative
measure of environmental influences such as dietary factors, drugs, chemical pollutants, behavioral
factors and socio-economic factors, and associated biological responses throughout the lifespan [9].
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Animal studies and epidemiology suggest that environmental chemicals likely play diverse
biological roles in the development of breast cancer, with some exposures important early in life
and others important in mid- or late-life. For example, our recent review of biological evidence and
epidemiologic studies found a higher risk of breast cancer for exposures to dioxins, air pollution,
dichlorodiphenyltrichloroethane (DDT), and perflurooctanesulfonamide (PFOSA) during breast
development, and for occupational exposures to solvents and other mammary carcinogens such
as gasoline components [10].
However, most epidemiological studies investigating environmental contribution to breast
cancer risk have focused on a limited set of exposures and outcomes based on a priori knowledge
and, as a result, are likely to miss important relationships. In addition, these studies have almost
exclusively assessed the risks of exposure to single chemicals. In order to reduce the burden of breast
cancer, there is an urgent need to find the undiscovered environmental risk factors. One promising
approach is to conduct exposome-wide association studies (EWAS) that measure a rich set of molecular
information from both exogenous and endogenous sources in biospecimens and identify associations
with breast cancer [11,12]. Systems-based approaches that utilize “omics” technologies are now
emerging as powerful approaches for mapping the exposome in order to discover features associated
with higher risk.
2. Approaches and Methods
The objective of this research program is to measure a myriad of environmental exposures (i.e.,
the exposome), evaluate their interactions with genetic factors, and assess their associations with health
outcomes and/or biological pathways related to breast cancer (e.g., chronic inflammation, breast density,
and hormones levels) (Figure 1). We hypothesize that by measuring a rich set of molecular information
(e.g., small molecules, protein, and DNA adducts) in archived biospecimens and using a case-control
design where cases have breast cancer or defined by phenotypic measures associated with breast
cancer (e.g., chronic inflammation and breast density), EWAS can pinpoint novel environmental risk
factors associated with these outcomes [13–15]. This approach has been successfully used to discover
novel risk factors for type 2 diabetes [16], blood pressure [17] and all-cause of mortality [18] in the
U.S. Ideally, EWAS should be perform using a prospective study design with molecular information
measured in prediagnostic biospecimens for establishing causality.
2.1. Capturing Molecular Information Using Omics
Metabolomics is recognized as a powerful platform for detecting small molecules in
biospecimens [19,20]. These small molecules can be either substrates or end products of cellular
metabolism and can originate from exogenous sources via inhalation, ingestion and dermal absorption,
or from endogenous processes including human and microbial metabolism. Very few metabolomics
studies have explored associations of environmental exposures with the risk of breast cancer.
A recent nested case-control study has evaluated associations between diet-related metabolites
and postmenopausal breast cancer [21]. Among 113 prediagnostic diet-related metabolites—identified
by computing partial correlations between serum metabolites and food items—three were associated
with overall breast cancer risk (N = 621 cases) and nineteen with estrogen receptor positive breast
cancer (N = 418 cases), including saturated fatty acids (from fats/oils), vitamin E derivatives (from
desserts or vitamin supplements) and androgens (from alcohol), with ORs ranging from 0.6 to 2.2.
The main challenge with the use of non-targeted metabolomics based on high-resolution mass
spectrometry (HRMS) is the annotation (i.e., identification) of small molecules. The first step for the
annotation of metabolomics features relies on matching accurate mass of detected features to known
small molecules present in public databases such as the Human Metabolome Database (HMDB) [22] or
the METLIN database [23]. These databases contain information about more than 100,000 endogenous
and exogenous metabolites, but very few entries are related to environmental chemicals. Therefore,
metabolite databases must be extended by creating databases of environmental chemicals.
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Figure 1. Conceptual diagram. Exposome-wide association studies using a prospective case-control 
design can discover novel environmental risk factors related to breast cancer. The exposome includes 
measurements of a rich set of molecular information in prediagnostic biospecimens. Cases can be 
breast cancer cases or cases with phenotypic measures related to breast cancer. 
Data resources that are now available from the US Environmental Protection Agency (EPA) and 
other sources provide valuable information to help build environmental chemical databases that are 
relevant to breast cancer. To start, very large exogenous chemical libraries are available such as the 
EPA’s Distributed Structure-Searchable Toxicity (DSSTOX; ~875,000 chemicals) [24] or PubChem (6.5 
million unique chemical structures) [25]. While these provide coverage of the chemical space, they 
contain so many chemicals that they may not be helpful in targeting chemicals that are ongoing 
exposures or that are plausible breast carcinogens, and there will be many chemicals matching to the 
mass of each observed peak. Thus, new approaches are needed to narrow these large databases to focus 
on chemicals with likely exposures and likely relevant biological effects. For example, we recently 
applied this approach to identify novel chemical exposures in a cohort of California women firefighters 
and office workers. Metabolomics analysis of serum samples showed tentative matches to more than 
600 chemicals from our in-house database of 740 slightly polar and acidic compounds expected to 
have widespread exposures [26].  
Additional opportunities to develop relevant chemical databases for annotating tentative chemical 
matches would use available data from EPA on expected population exposures and mechanisms of 
toxicity. For example, EPA has used high throughput modeling along with information on 
production volumes, chemical properties, and some chemical use information to predict population 
exposures for almost 500,000 chemicals. These data may be used to prioritize chemicals for a database. 
For example EPA’s modeling predicted 1880 chemicals would have median population exposures 
above 0.1 mg/kg-day [27]. Chemical databases should also be developed that feature chemicals 
shown to be active in breast cancer-related pathways, such as estrogen receptor activation or DNA 
Figure 1. Conceptual diagram. Exposome-wide association studies using a prospective case-control
design can discover novel environmental risk factors related to breast cancer. The exposome includes
measurements of a rich set of molecular information in prediagnostic biospecimens. Cases can be
breast cancer cases or cases with phenotypic measures related to breast cancer.
Data resources that are now available from the US Environmental Protection Agency (EPA) and
other sources provide valuable information to help build environmental chemical databases that
are relevant to breast cancer. To start, very large exogenous chemical libraries are available such as
the EPA’s Distributed Structure-Searchable Toxicity (DSSTOX; ~875,000 chemicals) [24] or PubChem
(6.5 million unique chemical structures) [25]. While these provide coverage of the chemical space,
they contain so many chemicals that they may not be helpful in targeting chemicals that are ongoing
exposures or that are plausible breast carci s, t ere ill be many chemicals matching to the
mass of each observed peak. Thus, ne a e ed to na row these large d taba es t focus
on chemicals with likely exposures and likel rel l ical effects. For example, we r cently
applied this approach to identify novel che i i a cohort of California women firefighters
and office workers. Metabolomics analysis f r les showed tentative matches to more than
600 chemicals from our in-house database of 740 slightly polar and acidic compounds expected to have
widespread exposures [26].
Additional opportunities to develop relevant chemical databases for annotating tentative chemical
matches would use available data from EPA on expected population exposures and mechanisms
of toxicity. For example, EPA has used high throughput modeling along with information on
production volumes, chemical properties, and some chemical use information to predict population
exposures for almost 500,000 chemicals. These data may be used to prioritize chemicals for a database.
For example EPA’s modeling predicted 1880 chemicals would have median population exposures
above 0.1 mg/kg-day [27]. Chemical databases should also be developed that feature chemicals shown
to be active in breast cancer-related pathways, such as estrogen receptor activation or DNA damage.
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These chemicals can also be extracted from EPA’s ToxCast data, which includes results from over 700
different in vitro activity assays for 3000 chemicals [24].
Another challenge with annotation of metabolomics features is that it is often not possible to identify
compounds simply based on accurate mass since several molecules with different structures exhibit
similar mass. Therefore, successful studies should utilize HRMS to produce MS/MS fragmentation
spectra. The generated MS/MS spectra will provide structural information specific to each molecule to
guide identification of compounds.
It is also important to note that non-targeted metabolomics analysis using HRMS is less sensitive,
compared to targeted HRMS analysis, and therefore exposures to very low levels of environmental
factors may be missed. New tools and approaches to improve the sensitivity of non-targeted HRMS
metabolomics analysis would be greatly encouraged.
Adductomics is another top-down technique that measures modifications of blood proteins like
hemoglobin (Hb) or human serum albumin (HSA) to characterize exposures to reactive electrophiles
that are inherently toxic but cannot be measured directly in biospecimens [11]. By characterizing
a complete adductome—via non-targeted HRMS analysis of adducts of DNA, HSA, and Hb—it is
possible to map systemic exposures that occurred over the in vivo residence time of the nucleophile
(i.e., blood protein), which can range from hours to months [15,28]. This approach has been recently
used to identify protein modifications of HSA in serum samples from Chinese workers exposed
to benzene [29] as well as adducts produced by microbial metabolites and their relationships with
colorectal cancer in a case-control study of Italian [30].
The integration of data from multiple omics platforms would provide a more holistic understanding
of gene-environment interactions in breast cancer pathogenesis compared to single omics approaches
analyzed in isolation. However, multi-omics integration faces several challenges such as data
harmonization, large number of false positive results, inadequate data visualization tools, and metabolic
pathway databases.
2.2. Resources Needed
This research program would need to be carried out by a multidisciplinary team with expertise
in omics measurements, bioinformatics, breast cancer biology, toxicology (including computational
toxicology), and epidemiology. EPA data on short term toxicity testing and exposure modeling are
publicly available and can be used to build libraries of breast cancer-relevant chemicals. The proposed
research could leverage existing cohorts, which have archived biological specimens and have collected
extensive health information, including known risk factors for breast cancer and breast cancer outcomes
or phenotypes relevant to breast cancer. California is well positioned to carry out this research idea,
with several state-of-the-art omics platforms, researchers with relevant expertise, and access to existing
cohorts of adult women and young girls with archived biological specimens suitable for omics and
information on breast cancer risk factors (e.g., the Child Health and Development Studies CHDS, Avon
Army of Women, and the Sister Study). Projects designed to meet these objectives will need budgets in
the range of $1 M/year for 4–5 years.
3. Expected Results and Discussion
We anticipate that this research program will build and demonstrate a new approach combining
omics and phenotypic measurements to investigate associations of an unprecedentedly wide spectrum
of exposures (i.e., exogenous and endogenous) with phenotypic measures, which will provide unique
opportunities to discover novel environmental risk factors for breast cancer and bring new insights
into molecular mechanisms of these relationships. Two key innovative elements are application and
integration of omics approaches to identify differences between participants with and without breast
cancer or breast cancer risk factors, and the creation of a new breast cancer-related chemical library of
pharmaceuticals, food and consumer product chemicals, and pollutants that have biological activities
similar to known breast carcinogens. The use of MS/MS fragmentation profiles will provide critical
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structural information to get more confident identification of compounds. Use of newly available
databases of short-term toxicity and exposure predictions for thousands of chemicals to identify breast
cancer-related chemicals is also novel as an approach for building a metabolomics compound database.
Findings from this program will provide a newly extended list of breast cancer-related
environmental factors and strengthen scientific support for reducing exposure to such factors
by providing novel data about human exposures from diet, lifestyle factors, and chemicals that
are associated with health outcomes and/or pathways related to breast cancer. We also expect
that this program will identify endogenous mediators of the relationships between exposures and
breast cancer-related phenotypes, providing new insights about molecular mechanisms underlying
exposure–outcome relationships. This will further our understanding of how environmental exposures
interact with genetics and impact women’s health, and will ultimately help develop prevention
strategies and lower the incidence of breast cancer. Projects that would stratify women based on
menopausal status, race/ethnicity and socio-economic level would provide an opportunity to also
evaluate disparities in estimated breast cancer risk from exposure to environmental factors and identify
disproportionately affected populations.
4. Conclusions
We hypothesize that by measuring a rich set of molecular information with omics
(e.g., metabolomics and adductomics) and comparing these profiles using a case-control design
we can pinpoint novel environmental risk factors for breast cancer. Specifically, exposome-wide
association study (EWAS) approaches can be used to compare molecular profiles between controls
and either breast cancer cases or participants with phenotypic measures associated with breast cancer
(e.g., high breast density and chronic inflammation). Current challenges in annotating compound
peaks from biological samples can be addressed by creating libraries of environmental chemicals that
are breast cancer relevant using publicly available high throughput exposure and toxicity data, and by
mass spectra fragmentation. This line of discovery and innovation will extend understanding of how
environmental exposures interact with genetics to affect health, and provide evidence to support new
breast cancer prevention strategies.
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